Hematologic aspects of myeloablative therapy and bone marrow transplantation

Journal of Clinical Laboratory Analysis

Volumn 19, Issue 2, 2005, Pages 47-79

  Riley, Roger S ^a,d   Idowu, Michael ^a   Chesney, Alden ^a   Zhao, Shawn ^a   McCarty, John ^a   Lamb, Lawrence S ^b,c   Ben Ezra, Jonathan M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Bone marrow pathology; Bone marrow transplantation; Complications; Graft versus host disease; Hematopoietic reconstitution; Immunophenotyping; Myeloablative therapy

Indexed keywords

ALKYLATING AGENT; AMSACRINE; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; INTERFERON; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; BLOOD CELL COUNT; BONE MARROW BIOPSY; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CYTOGENETICS; FLOW CYTOMETRY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFECTION; LYMPHOPROLIFERATIVE DISEASE; MYELOABLATIVE THERAPY; MYELOFIBROSIS; PATIENT MONITORING; RECURRENT DISEASE; REVIEW; SPINAL CORD DISEASE; THERAPY; TREATMENT INDICATION;

BONE MARROW TRANSPLANTATION; HEMATOLOGIC DISEASES; HEMATOPOIESIS; HUMANS; IMMUNE SYSTEM DISEASES; MONITORING, PHYSIOLOGIC; TRANSPLANTATION CONDITIONING;

EID: 15244351563     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcla.20055     Document Type: Review

References (231)

1. Margolis J, Vogelsang G. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease. Semin Oncol 2000;27:72-77.
2. Appelbaum FR. The current status of hematopoietic cell transplantation. Annu Rev Med 2003;54:491-512.
3. Horwitz EM. Bone marrow transplantation: it's not just about blood anymore! Pediatr Transplant 2003;7(Suppl 3):56-58.
4. Storb R. Allogeneic hematopoietic stem cell transplantation-yesterday, today, and tomorrow. Exp Hematol 2003;31: 1-10.
5. Thomas ED. Landmarks in the development of hematopoietic cell transplantation. World J Surg 2000;24:815-818.
6. Beatty PG. Bone marrow transplantation. In: McClatchey KD, editor. Clinical laboratory medicine. 2nd edition. Philadelphia: Lippincott, Williams, and Wilkins; 2002. p 779-786.
7. Barker JN, Wagner JE. Umbilical cord blood transplantation: current state of the art. Curr Opin Oncol 2002;14:160-164.
8. Jansen J, Thompson JM, Dugan MJ, et al. Peripheral blood progenitor cell transplantation. Ther Apher 2002;6:5-14.
9. Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 2003;101:4233-4244.
10. Bensinger WI, Storb R. Allogeneic peripheral blood stem cell transplantation. Rev Clin Exp Hematol 2001;5:67-86.
11. Hansson M, Svensson A, Engervall P. Autologous peripheral blood stem cells: collection and processing. Med Oncol 1996;13:71-79.
12. Van Hoef ME. Guidelines for efficient peripheral blood progenitor cell collection. Neth J Med 1996;48:29-37.
13. Herve P. Donor-derived hematopoietic stem cells in organ transplantation: technical aspects and hurdles yet to be cleared. Transplantation 2003;75(Suppl):55S-57S.
14. Anasetti C. Advances in unrelated donor hematopoietic cell transplantation. Haematologica 2003;88:246-249.
15. Devine SM, Adkins DR, Khoury H, Brown RA, Vij R, Blum W, DiPersio JF. Recent advances in allogeneic hematopoietic stem-cell transplantation. J Lab Clin Med 2003;141:7-32.
16. Lamb LS Jr. Hematopoietic cellular therapy: implications for the flow cytometry laboratory. Hematol Oncol Clin North Am 2002;16:455-476.
17. Gupta V, Lazarus H, Keating A. Myeloablative conditioning regimens for AML allografts: 30 years later. Bone Marrow Transplant 2003;32:969-978.
18. Cwynarski K, Craddock C, Cobbold M, Apperley J, Goldman J. Survival after bone-marrow transplantation. Lancet 2002;359: 887-888.
19. Baden LR. Prevention and therapy of fungal infections in bone marrow transplantation. Leukemia 2003;17:1038-1041.
20. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101:407-414.
21. Gosselin MV, Adams RH. Pulmonary complications in bone marrow transplantation. J Thorac Imaging 2002;17:132-144.
22. Tabbara IA, Zimmerman K, Morgan C, Nahleh Z. Allogeneic hematopoietic stem cell transplantation. Arch Intern Med 2002; 162:1558-1566.
23. Gatt ME, Liebster D, Leibowitz D, Matzner Y. Acute myocardial infarction after bone marrow transplantation: an unsuspected late complication. Ann Hematol 2003;82:136-138.
24. Jones AD, Maziarz R, Gilster J, Domreis J, Deveney CW, Sheppard BC. Surgical complications of bone marrow transplantation. Am J Surg 2003;185:481-484.
25. Schulenburg A, Turetschek K, Wrba F, et al. Early and late gastrointestinal complications after myeloablative and nonmyeloablative allogeneic stem cell transplantation. Ann Hematol 2004;83:101-106.
26. Champlin R, Khouri I, Anderlini P. et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology 2003;17:94-100; discussion 103-107.
27. Georges GE, Storb R. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation. Int J Hematol 2003;77:3-14.
28. Luznik L, O'Donnell PV, Fuchs EJ. Nonmyeloablative alternative donor transplants. Curr Opin Oncol 2003;15:121-126.
29. Childs R, Barrett J. Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy. Semin Hematol 2002;39:63-71.
30. Childs R, Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J 2002;8:2-11.
31. Childs RW. Nonmyeloablative allogeneic peripheral blood stem-cell transplantation as immunotherapy for malignant diseases. Cancer J Sci Am 2000;6:179-187.
32. McCarthy NJ, Bishop MR. Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations. Oncologist 2000;5:487-496.
33. Champlin R, Khouri I, Anderlini P, et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 2001;27(Suppl 2):S13-S22.
34. Maris M, Woolfrey A, McSweeney PA, et al. Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century. Front Biosci 2001;6:G13-G16.
35. Pulsipher MA, Woolfrey A. Nonmyeloablative transplantation in children. Current status and future prospects. Hematol Oncol Clin North Am 2001;15:809-834, vii-viii.
36. Baron F. Beguin Y. Nonmyeloablative allogeneic hematopoietic stem cell transplantation. J Hematother Stem Cell Res 2002;11: 243-263.
37. Mielcarek M, Sandmaier BM, Maloney DG, et al. Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. J Clin Immunol 2002;22:70-74.
38. Naeim F, Smith GS, Gale RP. Morphologic aspects of bone marrow transplantation in patients with aplastic anemia. Hum Pathol 1978;9:295-308.
39. Foucar K. 1995. Effects of therapy and transplantation, and detection of minimal residual disease. In: Foucar K, editor. Bone marrow pathology. Chicago: ASCP Press, p 531-540.
40. Rose MS, Leahy MF, Stevens A, Black PJ, Barkhan P. The bone marrow during recovery from drug induced agranulocytosis. Guys Hosp Rep 1972;121:147-153.
41. Thomas ED, Marmont AM, Sale GE. 1988. Aplastic anemia and hematopoiesis after bone marrow transplantation. In: Zucker-Franklin D, Greaves MF, Grossi CE, Marmont AM, editors. Atlas of blood cells. 2nd edition. Philadelphia: Lea & Febiger. p 733-760.
42. van den berg H, Kluin PM, Zwaan FE, Vossen JM. Histopathology of bone marrow reconstitution after allogeneic bone marrow transplantation. Histopathology 1989;15: 363-373.
43. van den Berg H, Kluin PM, Vossen JM. Early reconstitution of haematopoiesis after allogeneic bone marrow transplantation: a prospective histopathological study of bone marrow biopsy specimens. J Clin Pathol 1990;43:365-369.
44. Michelson JD, Gornet M, Codd T, Torres J, Lanighan K, Jones R. Bone morphology after bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Exp Hematol 1993;21: 475-482.
45. Domenech J, Roingeard F, Binet C. The mechanisms involved in the impairment of hematopoiesis in autologous bone marrow transplantation. Leuk Lymphoma 1997;24:239-256.
46. Galotto M, Berisso G, Delfino L, et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 1999;27:1460-1466.
47. Cline MJ, Gale RP, Golde DW. Discrete clusters of hematopoietic cells in the marrow cavity of man after bone marrow transplantation. Blood 1977;50:709-712.
48. Turhan AG, Humphries RK, Phillips GL, Eaves AC, Eaves CJ. Clonal hematopoiesis demonstrated by X-linked DNA polymorphisms after allogeneic bone marrow transplantation. N Engl J Med 1989;320:1655-1661.
49. Thiele J, Kvasnicka HM, Beelen DW, Wenzel P, Koepke ML, Leder LD, Schaefer UW. Macrophages and their subpopulations following allogenic bone marrow transplantation for chronic myeloid leukaemia. Virchows Arch 2000;437:160-166.
50. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features. Am J Clin Pathol 2000;114:57-65.
51. Creagh MD, Clark DJ, Collin RC. Restitution of normal marrow morphology and karyotype in acute refractory acute promyelocytic leukaemia with all-trans retinoic acid. Br J Haematol 1991;78:572.
52. Dulaney AM, Murgatroyd RJ. Use of trans-retinoic acid in the treatment of acute promyelocytic leukemia. Ann Pharmacother 1993;27:211-214.
53. Keever-Taylor CA, Klein JP, Eastwood D, Bredeson C, Margolis DA, Burns WH, Vesole DH. Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34(+) cell dose. Bone Marrow Transplant 2001;27: 791-800.
54. Szilvassy SJ, Meyerrose TE, Ragland PL, Grimes B. Differential homing and engraftment properties of hematopoietic progenitor cells from murine bone marrow, mobilized peripheral blood, and fetal liver. Blood 2001;98:2108-2115.
55. Ryder JW, Lazarus HM, Farhi DC. Bone marrow and blood findings after marrow transplantation and rhGM-CSF therapy. Am J Clin Pathol 1992;97:631-637.
56. Burt RK. Clinical utility in maximizing CD34+ cell count in stem cell grafts. Oncologist 1999;4:265-268.
57. Stewart DA, Guo D, Luider J, et al. Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to the total CD34+ cell dose. Bone Marrow Transplant 1999;23:1237-1243.
58. Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002;99:2726-2733.
59. Gordon MY. Relevance of colony forming assays to bone marrow transplantation with particular reference to grafting for aplastic anaemia. Br J Haematol 1979;42:61-71.
60. Serke S, Sauberlich S, Huhn D. A liquid culture method for the in vitro growth of hemopoietic progenitor cells from normal human adult peripheral blood allowing for analysis by multiparameter flow-cytometry. Eur J Haematol 1991;46:85-92.
61. van der Wall E, Richel DJ, Holtkamp MJ, et al. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol 1994;5:795-802.
62. Schwella N, Siegert W, Beyer J, et al. Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution. Ann Hematol 1995;71: 227-234.
63. Schwella N, Beyer J, Schwaner I, et al. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol 1996;14:1114-1121.
64. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984;133:157-165.
65. Civin CI, Banquerigo ML, Strauss LC, Loken MR. Antigenic analysis of hematopoiesis. VI. Flow cytometric characterization of My-10-positive progenitor cells in normal human bone marrow. Exp Hematol 1987;15:10-17.
66. Fackler MJ, Civin CI, Sutherland DR, Baker MA, May WS. Activated protein kinase C directly phosphorylates the CD34 antigen on hematopoietic cells. J Biol Chem 1990;265: 11056-11061.
67. Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood 1996;87:1-13.
68. Ravagnani F, Siena S, Bregni M, et al. Methodologies to estimate circulating hematopoietic progenitors for autologous transplantation in cancer patients. Haematologica 1991;76(Suppl 1):46-49.
69. Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991;77:400-409.
70. Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998;4:84-92.
71. Scheid C, Draube A, Reiser M, et al. Using at least 5 × 10(6)/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transplant 1999;23: 1177-1181.
72. Kuse R. The appearance of reticulocytes with medium or high RNA content is a sensitive indicator of beginning granulocyte recovery after aplasiogenic cytostatic drug therapy in patients with AML. Ann Hematol 1993;66:213-214.
73. Davis BH, Bigelow N, Ball ED, Mills L, Cornwell GG III. Utility of flow cytometric reticulocyte quantification as a predictor of engraftment in autologous bone marrow transplantation. Am J Hematol 1989;32:81-87.
74. Sica S, Salutari P, Laurenti L. et al. Highly fluorescent reticulocytes after CD34+ peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998;21:361-364.
75. Sica S, Sora F, Laurenti L, et al. Highly fluorescent reticulocyte count predicts haemopoietic recovery after immunosuppression for severe aplastic anaemia. Clin Lab Haematol 1999;21:387-389.
76. George P, Wyre RM, Bruty SJ, Sweetenham JW, Duncombe AS. Automated immature reticulocyte counts are early markers of engraftment following autologous PBSC transplantation in patients with lymphoma. J Hematother Stem Cell Res 2000;9: 219-223.
77. Flow cytometric reticulocyte quantification in the evaluation of hematologic recovery. Spanish Multicentric Study Group for Hematopoietic Recovery. Eur J Haematol 1994;53:293-297.
78. Lazarus HM, Chahine A, Lacerna K, et al. Kinetics of erythrogeriesis after bone marrow transplantation. Am J Clin Pathol 1992;97:574-583.
79. Torres A, Sanchez J, Lakomsky D, et al. Assessment of hematologic progenitor engraftment by complete reticulocyte maturation parameters after autologous and allogeneic hematopoietic stem cell transplantation. Haematologica 2001;86:24-29.
80. Remacha AF, Martino R, Sureda A, et al. Changes in reticulocyte fractions during peripheral stem cell harvesting: role in monitoring stem cell collection. Bone Marrow Transplant 1996;17:163-168.
81. Ault KA, Antin JH, Ginsburg D, et al. Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med 1985;161:1483-1502.
82. Antin JH, Ault KA, Rappeport JM, Smith BR. B lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes. J Clin Invest 1987;80:325-332.
83. Lum L. The kinetics of immune reconstitution after human bone marrow transplantation. Blood 1987;69:369-380.
84. Fallen PR, McGreavey L, Madrigal JA, et al. Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant 2003;32:1001-1014.
85. Lewis NL, Mullaney M, Mangan KF, Klumpp T, Rogatko A, Broccoli D. Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients. Bone Marrow Transplant 2004;33:71-78.
86. Morecki S, Gelfand Y, Nagler A, et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001;28:243-249.
87. Schaap N, Schattenberg A, Mensink E, et al. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation. Leukemia 2002;16:13-21.
88. Del Toro G, Satwani P, Harrison L, et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004;.
89. Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, Weisdorf D. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2001;7:473-485.
90. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-763.
91. Bornhauser M, Thiede C, Platzbecker U, et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001;7:2254-2262.
92. Friedman TM, Varadi G, Hopely DD, et al. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches. Biol Blood Marrow Transplant 2001;7:656-664.
93. Nagler A, Aker M, Or R, Naparstek E, Varadi G, Brautbar C, Slavin S. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 2001;29:362-370.
94. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002;99:1071-1078.
95. Kernan NA, Bordignon C, Heller G, et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. Blood 1989;74:2227-2236.
96. Lamb LS Jr., Robbins NF, Abhyankar S, Joyce M, Stetler-Stevenson M, Henslee-Downey PJ, Gee AP. Flow cytometric cell sorting combined with molecular chimerism analysis to detect minimal recurrent leukemia: good news and bad news. Bone Marrow Transplant 1997;19:1157-1161.
97. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997;89: 3048-3054.
98. Georges GE, Storb R, Thompson JD, Yu C, Gooley T, Bruno B, Nash RA. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. Blood 2000;95:3262-3269.
99. de Weger RA, Tilanus MG, Scheidel KC, van den Tweel JG, Verdonck LF. Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats. Br J Haematol 2000;110:647-653.
100. Bryant E, Martin PJ. Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic cell transplantation. Oxford, London: Blackwell Science; 1999. p 197-206.
101. Ferrand C, Perruche S, Robinet E, Martens A, Tiberghien P, Saas P. How should chimerism be decoded? Transplantation 2003;75(Suppl):50S-54S.
102. Lawler M, Humphries P, McCann SR. Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction. Blood 1991;77:2504-2514.
103. Lapointe C, Forest L, Lussier P, et al. Sequential analysis of early hematopoietic reconstitution following allogeneic bone marrow transplantation with fluorescence in situ hybridization (FISH). Bone Marrow Transplant 1996;17:1143-1148.
104. Dewald G, Stallard R, Al Saadi A, et al. A multicenter investigation with interphase fluorescence in situ hybridization using X- and Y-chromosome probes. Am J Med Genet 1998;76:318-326.
105. Thiede C, Florek M, Bornhauser M, et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999;23:1055-1060.
106. Pindolia K, Janakiraman N, Kasten-Sportes C, Demanet C, Van Waeyenberge C, Pals G, Worsham MJ. Enhanced assessment of allogeneic bone marrow transplant engraftment using automated fluorescent-based typing. Bone Marrow Transplant 1999;24: 1235-1241.
107. Nollet F, Billiet J, Selleslag D, Criel A. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transplant 2001;28:511-518.
108. Thiede C, Bornhauser M, Ehninger G. Evaluation of STR informativity for chimerism testing-comparative analysis of 27 STR systems in 203 matched related donor recipient pairs. Leukemia 2004;18:248-254.
109. Briones J, Urbano-Ispizua A, Rozman C, et al. Study of hematopoietic chimerism following allogeneic peripheral blood stem cell transplantation using PCR amplification of short tandem repeats. Ann Hematol 1996;72:265-268.
110. Scharf SJ, Smith AG, Hansen JA, McFarland C, Erlich HA. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 1995;85:1954-1963.
111. McCann SR, Lawler M. Mixed chimaerism; detection and significance following BMT. Bone Marrow Transplant 1993;11: 91-94.
112. Roux E, Helg C, Dumont-Girard F, Chapuis B, Jeannet M, Roosnek E. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996;87: 3984-3992.
113. Socie G, Lawler M, Gluckman E, McCann SR, Brison O. Studies on hemopoietic chimerism following allogeneic bone marrow transplantation in the molecular biology era. Leuk Res 1995;19: 497-504.
114. Slavin S. Immunotherapy of cancer with alloreactive lymphocytes. N Engl J Med 2000;343:802-803.
115. Exner BG, Acholonu I, Ildstad ST. Hematopoietic chimerism, tolerance induction and graft-versus-host disease: considerations for composite tissue transfer. Transplant Proc 1998;30: 2718-2720.
116. Bader P, Klingebiel T, Schaudt A, et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999;13:2079-2086.
117. Schattenberg A, Schaap N, Van De Wiel-Van Kemenade E, et al. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion. Leuk Lymphoma 1999;32:317-325.
118. Blazar BR, Lees CJ, Martin PJ, Noelle RJ, Kwon B, Murphy W. Taylor PA. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J Immunol 2000;165: 4901-4909.
119. Tobal K, Newton J, Macheta M, et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000;95:815-819.
120. Lion T, Daxberger H, Dubovsky J, et al. Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation. Leukemia 2001;15:307-310.
121. Lion T, Muller-Berat N. Chimerism testing after allogeneic stem cell transplantation: importance of timing and optimal technique for chimerism testing in different clinical-biological situations. Leukemia 1999;13:2059.
122. Lion T. Chimerism testing after allogeneic stem cell transplantation: importance of timing and optimal technique for testing in different clinical-biological situations. Leukemia 2001;15:292.
123. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989;320: 197-204.
124. Quinones RR. Hematopoietic engraftment and graft failure after bone marrow transplantation. Am J Pediatr Hematol Oncol 1993;15:3-17.
125. Champlin R. Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia. Exp Hematol 1995;23:1148-1151.
126. Bruno B, Gooley T, Sullivan KM, Davis C, Bensinger WI, Storb R, Nash RA. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7:154-162.
127. Rosenthal NS, Farhl DC. Failure to engraft after bone marrow transplantation: bone marrow morphologic findings. Am J Clin Pathol 1994;102:821-824.
128. Foucar K. Bone marrow histiocytosis and autologous graft failure: possible implications. Am J Clin Pathol 1994;102: 713-714.
129. Thiele J, Kvasnicka HM, Beelen DW, Pilgram B, Rose A, Leder LD, Schaefer UW. Erythropoietic reconstitution, macrophages and reticulin fibrosis in bone marrow specimens of CML patients following allogeneic transplantation. Leukemia 2000;14:1378-1385.
130. Thiele J, Kvasnicka HM, Beelen DW, et al. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients. Mod Pathol 2001;14:129-138.
131. Bunjes D, Wiesneth M, Hertenstein B, Schmeiser T, Arnold R, Heit W. Graft failure after T cell-depleted bone marrow transplantation: clinical and immunological characteristics and response to immunosuppressive therapy. Bone Marrow Transplant 1990;6:309-314.
132. Cassileth PA, Gerson SL, Bonner H, Neiman RS, Lusk EJ, Hurwitz S. Identification of early relapsing patients with adult acute nonlymphocytic leukemia by bone marrow biopsy after initial induction chemotherapy. J Clin Oncol 1984;2:107-111.
133. Browman GP, Preisler HD. Predicting remission outcome in acute non-lymphocytic leukemia: general principles and their application to residual marrow leukemia. Leuk Res 1992;16: 511-519.
134. Steinherz PG, Gaynon PS, Breneman JC, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia-the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol 1996;14:389-398.
135. Kidd PG, Saminathan T, Drachtman RA, Ettinger LJ. Comparison of the cellularity and presence of residual leukemia in bone marrow aspirate and biopsy specimens in pediatric patients with acute lymphoblastic leukemia (ALL) at day 7-14 of chemotherapy. Med Pediatr Oncol 1997;29:541-543.
136. Schultz KR, Massing B, Spinelli JJ, Gaynon PS, Wadsworth L. Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia. Med Pediatr Oncol 1997;29:16-22.
137. Rimsza LM, Viswanatha DS, Winter SS, Leith CP, Frost JD, Foucar K. The presence of CD34+ cell clusters predicts impending relapse in children with acute lymphoblastic leukemia receiving maintenance chemotherapy. Am J Clin Pathol 1998;110:313-320.
138. Sebban C, Browman GP, Lepage E, Fiere D. Prognostic value of early response to chemotherapy assessed by the day 15 bone marrow aspiration in adult acute lymphoblastic leukemia: a prospective analysis of 437 cases and its application for designing induction chemotherapy trials. Leuk Res 1995;19:861-868.
139. Archimbaud E, Treille-Ritouet D, Guyotat D, Viala JJ, Fiere D. Day 4 bone marrow aspirate for prediction of resistance to induction chemotherapy in acute myeloid leukemia. Leuk Res 1987;11:281-283.
140. Peters WG, Willemze R, Zwaan FE, Colly LP. Day-6 bone marrow aspirate for the prediction of response to remission induction therapy for acute myelogenous leukaemia. Blut 1988; 57:91-95.
141. Preisler H, Barcos M, Reese P, Priore RL, Pothier L. Recognition of drug resistance during remission induction therapy for acute non-lymphocytic leukemia: utility of day 6 bone marrow biopsy. Leuk Res 1983;7:67-75.
142. Preisler HD, Epstein J, Barcos M, et al. Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside. Br J Haematol 1984;58:19-32.
143. Preisler HD, Priore R, Azarnia N, et al. Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements. Br J Haematol 1986;63:625-636.
144. Roberts MM, Juttner CA, To LB, Kimber RJ. Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease. Leuk Res 1988;12:817-821.
145. Shamdas GJ, Garewal HS, Roe DJ. Usefulness of bone-marrow biopsy during induction therapy for acute myeloid leukemia. Lancet 1992;339:178.
146. Stone RM, Maguire M, Goldberg MA, Antin JH, Rosenthal DS, Mayer RJ. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood 1988;71:690-696.
147. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Leder LD, Schaefer HE. Changing patterns of histological subgroups during therapy of Ph1+ chronic myelogenous leukaemia. Histopathology 2000; 37:355-362.
148. van Dongen JJ, Szczepanski T, de Bruijn MA, et al. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther 1996;2:121-133.
149. Stock W, Estrov Z. Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000;14: 1289-1305, viii-ix.
150. Campana D. Monitoring minimal residual disease in acute leukemia: expectations, possibilities and initial clinical results. Int J Clin Lab Res 1994;24:132-138.
151. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999;38:139-152.
152. Campana D, Neale GA, Coustan-Smith E, Pui CH. Detection of minimal residual disease in acute lymphoblastic leukemia: the St Jude experience. Leukemia 2001;15:278-279.
153. Porwit-MacDonald A, Bjorklund E, Lucio P, et al. BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000;14:816-825.
154. Sievers EL, Radich JP. Detection of minimal residual disease in acute leukemia. Curr Opin Hematol 2000;7:212-216.
155. Deptala A, Mayer SP. Detection of minimal residual disease. Methods Cell Biol 2001;64:385-420.
156. Dolken G. Detection of minimal residual disease. Adv Cancer Res 2001;82:133-185.
157. Felgar RE. Minimal residual disease detection by flow cytometry: can it serve as a predictor of future relapse? Leuk Res 2001;25:409-411.
158. Cazzaniga G, Rossi V, Biondi A. Monitoring minimal residual disease using chromosomal translocations in childhood ALL. Best Pract Res Clin Haematol 2002;15:21-35.
159. Kim YJ, Kim DW, Lee S, et al. Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML. Eur J Haematol 2002;68:272-280.
160. Longacre TA, Foucar K, Crago S, et al. Hematogones: a multiparameter analysis of bone marrow precursor cells. Blood 1989;73:543-552.
161. Davis RE, Longacre TA, Cornbleet PJ. Hematogones in the bone marrow of adults. Immunophenotypic features, clinical settings, and differential diagnosis. Am J Clin Pathol 1994;102: 202-211.
162. Rimsza LM, Larson RS, Winter SS, Foucar K, Chong YY, Garner KW, Leith CP. Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features. Am J Clin Pathol 2000;114:66-75.
163. Muehleck SD, McKenna RW, Gale PF, Brunning RD. Terminal deoxynucleotidyl transferase (TdT)-positive cells in bone marrow in the absence of hematologic malignancy. Am J Clin Pathol 1983;79:277-284.
164. Caldwell CW, Poje E, Helikson MA. B-cell precursors in normal pediatric bone marrow. Am J Clin Pathol 1991;95:816-823.
165. Kobayashi SD, Seki K, Suwa N, et al. The transient appearance of small blastoid cells in the marrow after bone marrow-transplantation. Am J Clin Pathol 1991;96:191-195.
166. Sandhaus LM, Chen TL, Ettinger LJ, Hirst-Allen A, Mehta K, Raskova J. Significance of increased proportion of CD10-positive cells in nonmalignant bone marrows of children. Am J Pediatr Hematol Oncol 1993;15:65-70.
167. McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001;98:2498-2507.
168. Kallakury BV, Hartmann DP, Cossman J, Gootenberg JE, Bagg A. Posttherapy surveillance of B-cell precursor acute lymphoblastic leukemia. Value of polymerase chain reaction and limitations of flow cytometry. Am J Clin Pathol 1999;111: 759-766.
169. Buckley RH. 27. Transplantation immunology: organ and bone marrow. J Allergy Clin Immunol 2003;111(Suppl):S733-S744.
170. Deeg HJ. New strategies for prevention and treatment of graft-versus-host disease and for induction of graft-versus-leukemia effects. Int J Hematol 2003;77:15-21.
171. Ferrara JLM, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Bone Marrow Transplant 1999;5:347-356.
172. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001;29: 259-277.
173. Reddy P, Ferrara JLM. Immunobiology of acute graft-versus-host disease. Blood Rev 2003;17:187-194.
174. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 2003;54:29-52.
175. Bishop M, Flowers MED, Foss FM, Couriel D. Emerging strategies in the treatment of chronic graft-versus-host disease. Blood Marrow Transplant Rev 2002;12:4-5.
176. Lee SJ, Vogelsang G, Gilman A, et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant 2002;8:32-39.
177. Foss FM. Emerging therapies for chronic graft-versus-host disease. Blood Marrow Transplant Rev 2002;12:8-11.
178. Kazama T, Miyazawa M, Tsuchiya S, Horii A. Proliferation of macrophage-lineage cells in the bone marrow, severe thymic atrophy, and extramedullary hematopoiesis of possible donor origin in an autopsy case of post-transplantation graft-versus-host disease. Bone Marrow Transplant 1996;18:437-441.
179. Atkinson K, Dodds A, Concannon A, Biggs J. Late onset transfusion-dependent anaemia with thrombocytopenia secondary to marrow fibrosis and hypoplasia associated with chronic graft-versus-host disease. Bone Marrow Transplant 1987;2: 445-449.
180. Okamoto T, Kanamaru A, Kakishita E, Nagai K. Stromal fibroblastic and hematopoietic progenitors in patients with graft-versus-host disease (GVHD). Int J Hematol 1991;54: 299-306.
181. Martinez-Jaramillo G, Gomez-Morales E, Sanchez-Valle E. Mayani H. Severe hematopoietic alterations in vitro, in bone marrow transplant recipients who develop graft-versus-host disease. J Hematother Stem Cell Res 2001;10:347-354.
182. Storek J, Witherspoon RP, Webb D, Storb R. Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease. Am J Hematol 1996;52:82-89.
183. Thiele J, Kvasnicka HM, Beelen DW, et al. Relevance and dynamics of myelofibrosis regarding hematopoietic reconstitution after allogeneic bone marrow transplantation in chronic myelogenous leukemia-a single center experience on 160 patients. Bone Marrow Transplant 2000;26:275-281.
184. Brunning RD, et al. Acute myeloid leukaemias and myelodysplastic syndromes, therapy-related. In: Jaffe ES, Harris NL, Stein H, et al., editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2001. p 89-91.
185. Zompi S, Viguie F. Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia. Leuk Lymphoma 2002;43:275-280.
186. Carli PM, Sgro C, Parchin-Geneste N, Isambert N, Mugneret F, Girodon F, Maynadie M. Increase therapy-related leukemia secondary to breast cancer. Leukemia 2000;14:1014-1017.
187. Aguiar RC. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma 1998;29:17-26.
188. Leone G, Voso MT, Sica S, Morosetti R, Pagano L. Therapy related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma 2001;41:255-276.
189. Haase D, Binder C, Hunger J, et al. Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. Leuk Res 2002;26:249-254.
190. Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 2001;98:11592-11597.
191. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica 1999;84:937-945.
192. Block AW, Carroll AJ, Hagemeijer A, Michaux L, van Lom K, Olney HJ, Baer MR. Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:401-412.
193. Pagano L, Mele L, Casorelli I, Fianchi L, Di Febo A, Leone G. Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. Haematologica 2000;85:1327-1329.
194. Pagano L, Pulsoni A, Mele L, Leone G. Clinical and epidemiological features of acute lymphoblastic leukemia following a previous malignancy. Leuk Lymphoma 2000;39:465-475.
195. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002;99:1909-1912.
196. Ellis M, Lishner M. Second malignancies following treatment in non-Hodgkin's lymphoma. Leuk Lymphoma 1993;9:337-342.
197. Ellis M, Ravid M, Lishner M. A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias. Leuk Lymphoma 1993;11:9-13.
198. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001;19:1405-1413.
199. Orazi A, Cattoretti G, Heerema NA, Sozzi G, John K, Neiman RS. Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies. Mod Pathol 1993;6:521-525.
200. Andersen MK, Christiansen DH, Jensen BA, Ernst P, Hauge G, Pedersen-Bjergaard J. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Br J Haematol 2001;114:539-543.
201. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993;7: 1975-1986.
202. Martinelli G, Testoni N, Zinzani PL, Biondi A, Cimino G, Tura S. Therapy-related acute leukemia associated with involvement of 11q23 after high grade non-Hodgkin lymphoma. Haematologica 1998;83:283-284.
203. Detourmignies L, Castaigne S, Stoppa AM, et al. Therapy-related acute promyelocytic leukemia: a report on 16 cases. J Clin Oncol 1992;10:1430-1435.
204. Secker-Walker LM, Moorman AV, Bain BJ, Mehta AB. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop. Leukemia 1998;12:840-844.
205. Atlas M, Head D, Behm F, et al. Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints. Leukemia 1998;12:1895-1902.
206. Pui CH, Relling MV, Rivera GK, et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 1995;9:1990-1996.
207. Karp JE, Smith MA. The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Semin Oncol 1997;24:103-113.
208. Quesnel B, Kantarjian H, Bjergaard JP. et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 1993;11: 2370-2379.
209. Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33: 395-400.
210. Dissing M, Le Beau MM, Pedersen-Bjergaard J. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? J Clin Oncol 1998;16:1890-1896.
211. de Witte T, Oosterveld M, Span B, Muus P, Schattenberg A. Stem cell transplantation for leukemias following myelodysplastic syndromes or secondary to cytotoxic therapy. Rev Clin Exp Hematol 2002;6:72-85; discussion 86-77.
212. Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000;18:963-971.
213. Brigden M, McKenzie M. Treating cancer patients. Practical monitoring and management of therapy-related complications. Can Fam Physician 2000;46:2258-2268.
214. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997;14:8-14.
215. Wagner HJ, Rooney CM, Heslop HE. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8:1-8.
216. Deeg HJ, Witherspoon RP. Risk factors for the development of secondary malignancies after marrow transplantation. Hematol Oncol Clin North Am 1993;7:417-429.
217. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342: 1514-1516.
218. Mihalov ML, Gattuso P, Abraham K, Holmes EW, Reddy V. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996;10: 248-255.
219. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 1997;10:136-145.
220. Libertiny G, Watson CJ, Gray DW, Welsh KJ, Morris PJ. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001;88:1330-1334.
221. Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: a review. J Clin Pathol 2000;53:248-254.
222. Birkeland SA, Hamilton-Dutoit S, Sandvej K, Andersen HM, Bendtzen K, Moller B, Jorgensen KA. EBV-induced post-transplant lymphoproliferative disorder (PTLD). Transplant Proc 1995;27:3467-3472.
223. Haque TJ, Crawford DH. Transmission of Epstein-Barr virus during transplantation. Rev Med Virol 1996;6:77-84.
224. Lucas KG, Pollok KE, Emanuel DJ. Post-transplant EBV induced lymphoproliferative disorders. Leuk Lymphoma 1997; 25:1-8.
225. Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001;3:60-69.
226. Lohrisch CA, Nevill TJ, Barnett MJ, et al. Development of a biologically distinct EBV-related lymphoproliferative disorder following autologous bone marrow transplantation for an EBV-negative post-renal allograft Burkitt's lymphoma. Leuk Lymphoma 2000;39:195-201.
227. Micallef IN, Chhanabhai M, Gascoyne RD, et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 1998;22:981-987.
228. Nalesnik MA. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002;159:9-18.
229. Orazi A, Hromas RA, Neiman RS, et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol 1997;107:419-429.
230. Posey LA, Kerschner JE, Conley SF. Posttransplantation lymphoproliferative disease in children: otolaryngologic manifestations and management. South Med J 1999;92:1079-1082.
231. Krech R, Thiele J. Histopathology of the bone marrow in toxic myelopathy. A study of drug induced lesions in 57 patients. Virchows Arch A Pathol Anat Histopathol 1985;405: 225-235.